期刊文献+

静脉连用左西孟旦对晚期心衰患者左室功能、心肌重构以及心脏生化标志物的影响 被引量:3

Effects of Levosimendan on left ventricular function, myocardial remodeling and cardiac biochemical markers in patients with terminal heart failure
原文传递
导出
摘要 目的 研究静脉连用左西孟旦对晚期心衰患者左室功能、心肌重构和心脏生化标志物的影响.方法 选取50例晚期心衰患者,在常规治疗的基础上静脉连用左西孟旦注射液治疗.通过测定每搏心输出量(SV)、心脏指数(CI)、左室射血分数(LVEF)、左室舒张末容积(LVEDV)等的变化,比较用药前后患者左室功能的改善、心肌重构的变化,以及对心脏生化标志物如心肌肌钙蛋白I(cTnI)、脑钠肽(BNP)、基质金属蛋白酶-9(MMP-9)等的影响.结果 左西孟旦静脉连用后治疗组患者呼吸困难及全身临床症状缓解,左室功能提升,SV、CI、LVEF均上升(P均<0.05),LVEDV及cTnI、BNP、MMP-9等的表达水平也不同程度地下降(P均<0.05).结论 左西孟旦连续用药能显著改善晚期心衰患者的左室功能,在一定程度上延缓了心肌重构的进展,并对心脏生化标志物产生了重大影响. Objective To study the effects of Levosimendan by continuous applications on left ventricular function,myocardial remodeling and cardiac biochemical markers in patients with terminal heart failure.Methods Fifty patients with advanced heart failure were chose.The patients were given levosimendan consecutively on the basis of conventional treatments.By measuring the cardiac output stroke volume (SV),cardiac index (CI),left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV) before and after treatment,the improvement of left ventricular function,the changes of myocardial remodeling,as well as the expression of the cardiac biochemical markers such as cTnI,BNP,MMP-9 were compared.Results Mter continous application of leosimendan,dyspnea and systemic clinical symptoms were relieved,left ventricular function were improved,SV,CI and LVEF were increased (P < 0.05),and LVEDV as well as expression levels of cTnI,BNP,MMP-9 also were differently decreased (P < 0.05).Conclusions Levosimendan can obviously improve left ventricular function in patients with terminal heart failure,extently delay the progress of myocardial reconstruction,and has significant impact on cardiac biochemical markers.
出处 《中国实用医刊》 2014年第23期45-48,共4页 Chinese Journal of Practical Medicine
关键词 左西孟旦 晚期心衰 左室功能 心肌重构 心脏生化标志物 Levosimendan Terminal heart failure Left ventricular function Myocardial remodeling Cardiac biochemical markers
  • 相关文献

参考文献19

  • 1Dec GW. Acute decompensated heart failure : the shrinking role of in- otropic therapy[J]. J Am Coll Cardiol, 2005, 46(1) : 65-67.
  • 2Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options [ J ]. Curt Opin Cardiol, 2004, 19(3) : 254-263.
  • 3黄峻,戴闺柱.慢性心力衰竭的诊断治疗指南[J].中华心血管病杂志,2007,35(12):834-865.
  • 4Franco F, Monteiro P, Goncalves F, et al. Prognostic value of BNPchanges in patients with decompensated advanced heart failure treated with levosimendan [ abstract ] [ J ]. Circulation, 2003, 108 ( Suppl 4) : 1V2447.
  • 5杜昕.钙增敏剂应用现状.长城心脏快讯,2005,2(10):39-41.
  • 6Pollesello P, Papp Z. The cardioprotective effect s of levosimendan: preclinical and clinical evidence [ J ]. J Cardiovasc Pharmacol, 2007, 50(3): 257-263.
  • 7Follat HF, Cleland JG, Just I-I, et al. Efficacy and safety of intrave- nous levosimendan compared with dobutamine insevere low-output heart failure( the LIDO study) : a randomized double-blind trial [ J]. Lancet, 2002, 360(9328): 196-202.
  • 8Zaman MJ, Vrotsou K, Chu GS, et al. A high incidental rise in car- diac troponin I carries a higher mortality risk in older patients than in those with a diagnosed acute coronary syndrome [ J ]. Age Ageing, 2011, 40(1) : 122-125.
  • 9Logear D, Beyne P, Cusson C, et al. Evidence of cardiac myolysis in severenonis chemic heart failure and the potential role of increased wall strain[J]. Am Heart J, 2001, 141 (2) : 247-253.
  • 10Gomes AV, Potter JD. Cellular and molecular aspects of familial hy- pertrophic cardio my op athy caused by mutations in the cardiac tropo- nin I gene [ J ]. Mol Cell Biochem, 2004, 263 (1-2) : 99-114.

二级参考文献30

  • 1朱红俊,龚少愚,邹逊,魏慧渊,陆曙.心力衰竭病因对血浆BNP水平的影响[J].临床荟萃,2007,22(1):27-28. 被引量:25
  • 2Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure [ J ]. CMAJ,2006,175:611-617.
  • 3See R ,de Lemos JA. Current status of risk stratification methods in acute coronary syndromes [ J ]. Curr Cardiol Rep,2006,8 : 282-288.
  • 4Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease:the present and the future [J]. J Am Coll Cardiol,2006,48:1-11.
  • 5Kerr A J, Raffel OC, Whalley GA, et al. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation [ J]. Eur Heart J,2008,29( 3 ) :363-370.
  • 6Takahashi N, Yamamoto A, Tezuka S, et al. Assessment of left ventricular dyssynchrony during development of heart failure by a novel program using ECG-gated myocardial perfusion SPECT [ J ]. Circ J,2008.72( 3 ) :370-377.
  • 7Sakuragi S, Maruo T, Taniguchi M, et al. Radial augmentation index associated with increase in B-type natriuretic peptide in patients with hypertension [J] . Int J Cardiol,2008,130(3) :414-419.
  • 8Kaski JP,Tome-Esteban MT,Mead-Regan SJ ,et al. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy [ J]. Heart ,2008,94(10) :1307-1311.
  • 9Suhr OB ,Anan I ,Backman C ,et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis [ J ] ? J Intern Med ,2008,263 (3) : 294-301.
  • 10Tsutamoto T,Sakai H ,Nishiyama K,et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure [ J ]. Circ J ,2007,71 (12) :1873-1878.

共引文献64

同被引文献23

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部